acid ingredients and double stranded (siRNA) using the potential to
revolutionize the treatment of cancer malignancy and other diseases where drugable
locates of disease are well recognized. The Companys current focus
will be on developing liposomal antisense drug individuals. Bio-Path also
anticipates developing liposome tumor concentrating on technology,Nike LeBron 10, representing
next-generation enhancements on the Companys core liposome delivery
technological innovation.
About Growth Receptor Bound protein-2 (Grb-2)
This adaptor protein Growth Receptor Bound protein-2 (Grb-2) is crucial
to cancer cell signaling since it is utilized by oncogenic tyrosine
kinases to induce cancers progression. Suppressing the purpose or
expression of Grb-2 must interrupt its vital signaling operate and
have a therapeutic application in cancer. BP-100.1.02 is a
neutral-charge, liposome-incorporated antisense drug substance intended
to inhibit Grb-2 expression.
Pertaining to Bio-Path Holdings, Inc,LeBron X.
Bio-Path is a biotechnology company focused on developing therapeutic
products utilizing its proprietary liposomal distribution technology
designed to systemically distribute nucleic acid solution drugs throughout the
human body which has a simple intravenous transfusion. Bio-Paths lead
product or service candidate, Liposomal Grb-2, is in a Phase I study for blood
cancers. Bio-Paths second drug prospect, also a liposomal antisense
drug,LeBron 10, is ready for your clinic where it will be analyzed in lymphoma and
If you need further information just follow this:
No comments:
Post a Comment